Cyclo Therapeutics : Factsheet

we are

Investment Summary

Leveraging over 3 decades of experience with cyclodextrins to advance clinically de-risked programs towards approval in diseases with unmet medical need

Platform Therapeutic

Technology

Platform technology has demonstrated to be safe and effective with over 10 years of patient exposure

Completion of enrollment in Pivotal Phase 3 study expected by year end 2023

Significant market opportunity with no approved therapy to treat both systemic and neurological manifestations of NPC

FDA: Orphan Drug Designation (ODD), Fast-Track, Rare Pediatric Disease Designation, potential PRV; EMA: ODD and adopted PIP

Alzheimer's Disease

Patient enrollment and dosing in Phase 2b study underway

Pipeline expansion into Alzheimer's Disease (AD), patent filed globally and is currently being executed

Cash Balance1	Market Cap3	Shares Outstanding2	Average Volume3
$5.2M	~$9M	10.5M	~91K

1: Pro Forma as of December 31, 2022 post the financing completed in January with single institutional investor; 2: As of March 15, 2023; 3: As of March 31, 2023 with a closing price of $0.84

Our Mission

We are dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases.

Our lead therapeutic asset, Trappsol® Cyclo™, is a proprietary formulation of hydroxypropyl beta cyclodextrin, and in multiple clinical studies has shown encouraging results to effectively manage the transportation of cholesterol. Taking the place of the defective NPC1 protein, Trappsol® Cyclo™, with its cyclic structure, facilitates the transport of accumulated cholesterol out of cellular lysosomes so it can be further processed and excreted out of cells. With the biologic similarities demonstrated between Niemann-Pick disease Type C1 and Alzheimer's disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in cerebrospinal fluid ("CSF"), and amyloid plaques in the brain, the Company believes Trappsol® Cyclo™ has significant potential to be an effective treatment option for Alzheimer's disease.

Our Team

N. Scott Fine	Joshua M. Fine	Karen Mullen, FFPM
Chief Financial Officer	Interim Chief Medical Officer
Chief Executive Officer
& Director

	Michael Lisjak	Lori McKenna Gorski
Jeffrey L. Tate, PhD	Global Head of Patient
Chief Regulatory Officer	Advocacy

Chief Operating Officer,

Chief Quality Officer

& Director

Platform Technology Pipeline

Trappsol® Cyclo™ allows for a multiple shots on goal model

Program

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Milestones

Trappsol® Cyclo™ Niemann-Pick Disease Type C

Trappsol® Cyclo™ Alzheimer's Disease

(Pivotal Phase 3 Study)

Completion of enrollment expected by year end 2023

Patient enrollment and dosing underway

Orphan Drug Designation in U.S. | Fast Track Status in U.S. | Potential for Priority Review Voucher (PRV) in U.S.

Orphan Drug Designation in EU | EMA Pediatric Investigational Plan Adopted

Therapeutic Focus Areas

Niemann-Pick Disease Type C (NPC)

Rare, fatal and progressive genetic disorder affecting the brain, liver, spleen and lungs

Characterized by a defect in the

NPC1 protein

Cholesterol and lipids accumulate in cells of major organs and tissues

Leading to cell and tissue dysfunction

1/100,000 Instances of NPC (~35 per year in U.S.)

0 U.S. Approved NPC Therapies

1 E.U Approved Therapy with No Systemic Effects

Alzheimer's Disease

The most common form of

Dementia

An irreversible, progressive neurologic disorder that slowly degrades memory, thinking and social skills that affects a person's ability to function independently

5 million+ people affected in the U.S.1

6th leading cause of death in the U.S.1

500,000 new cases every year2

13.8 million cases projected by 20501

Similarities: (1) Cognitive decline, (2) Elevated levels of tau, (3) Amyloid plaques

1. https://www.alz.org/alzheimers-dementia/facts-figures | 2. https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures

cyclotherapeutics.com | NASDAQ: CYTH | Investor Relations: JTC Team, [e-mail]